Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siZNF217
- Development stage
- Preclinical
- Lead developer
- University of Notre Dame
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
siZNF217 is a small interfering RNA (siRNA) designed to target and knock down the expression of Zinc finger protein 217 (ZNF217), a transcription factor and putative oncogene that is amplified in 20-30% of breast cancers. By silencing ZNF217, siZNF217 inhibits breast tumor progression, metastasis, and chemoresistance. Research indicates that knockdown of ZNF217 downregulates the secretion of angiogenic factors such as VEGF-A, PDGF-AA, and PDGF-AB/BB, thereby suppressing endothelial cell sprouting and angiogenesis. It also decreases the expression of VEGFR-2 (KDR) in breast cancer cells, suggesting an inhibition of autocrine VEGF-A signaling.
- Other names
- ZNF217 siRNAZNF-217 siRNAZNF 217 siRNAsi-ZNF217si-ZNF-217si-ZNF 217small interfering RNA targeting ZNF217
02
Targets
ZNF217 (Zinc finger protein 217)
Beyond the preview
Go deeper on siZNF217.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siZNF217.